The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.
A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.
Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.
This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Kidney Diseases Improving Global Outcomes: Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf. Accessed July 26, 2015
- Iron management in end-stage renal disease.Am J Kidney Dis. 1997; 29: 319-333
- Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systemic review and meta-analysis.Am J Kidney Dis. 2008; 52: 897-906
- Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.Pharmacotherapy. 2007; 27: 343-350
- Parenteral iron use in the management of anemia in end-stage renal disease patients.Am J Kidney Dis. 2000; 35: 1-12
- Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during dialysis.Kidney Int. 1999; 55: 1891-1898
- Iron transfer from transferrin to ferritin mediated by polyphosphate compounds.Biochim Biophys Acta. 1981; 677: 417-423
- Iron exchange between transferrin molecules mediated by phosphate compounds and other cell metabolites.Biochim Biophys Acta. 1977; 499: 169-177
- Pyrophosphate as a ligand for delivery of iron to isolated rat-liver mitochondria.Biochim Biophys Acta. 1984; 766: 233-239
- Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?.J Lab Clin Med. 2000; 136: 371-378
- Intravenous iron: from anathema to standard of care.Am J Hematol. 2008; 83: 580-588
- Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.Kidney Int. 2015; 88: 1187-1194
- Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.Nephrol Dial Transplant. 2015; 30: 2019-2026
U.S. National Institutes of Health. http://www.clinicaltrials.gov. Accessed July 6, 2016.
- Chronic administration of iron dextran into the peritoneal cavity of rats.Perit Dial Int. 1997; 17: 179-185
Published online: September 27, 2016
Accepted: August 29, 2016
© 2016 Elsevier Inc. All rights reserved.